Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 193 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AMG 193 + gemcitabine + nab-paclitaxel is a combination regimen under investigation for the treatment of advanced solid tumors with homozygous deletion of methylthioadenosine phosphorylase (MTAP), particularly gastrointestinal, biliary tract, and pancreatic cancers. AMG 193 is a CNS-penetrant, methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5), selectively inducing synthetic lethality in MTAP-deleted tumor cells. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor, and gemcitabine is a nucleoside analog and antimetabolite. The regimen is being studied for synergistic effects in MTAP-deleted tumors, with Phase 1 trials ongoing to establish safety and preliminary efficacy.
- Other names
- nab-paclitaxelnanoparticle albumin-bound paclitaxelgemcitabine
02
Targets
RRM1PRMT5 (Protein arginine N-methyltransferase 5)Microtubule
Beyond the preview
Go deeper on AMG 193 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 193 + gemcitabine + nab-paclitaxel.